2
Announcements
Trials
Browse
Landscape
Phase
Phase 2/3
2
Status
Recruiting
2
Sponsor Class
OTHER
2
Study Type
Interventional
2
Sponsor
Cancer Type
Other hematologic neoplasm
2
Lymphoid
2
Dermatologic
1
CNS
1
Conditions
Carcinoma, Non-Small-Cell Lung
10
Neoplasm Metastasis
5
Sarcoma
4
Neoplasms
4
Hematologic Neoplasms
4
Breast Neoplasms
4
Brain Neoplasms
4
Pancreatic Neoplasms
3
Melanoma
3
Glioma
3
Thyroid Cancer, Papillary
2
Salivary Gland Neoplasms
2
Prostatic Neoplasms
2
Ovarian Neoplasms
2
Neoplasms by Site
2
Neoplasms by Histologic Type
2
Lymphoproliferative Disorders
2
Leukemia, Myeloid, Acute
2
Central Nervous System Neoplasms
2
Wilms Tumor
1
Uveal Melanoma
1
Thrombocytosis
1
Solid Tumors
1
Solid Tumor
1
Sarcoma, Ewing
1
Recurrence
1
Rare Tumour
1
Primary Myelofibrosis
1
Precursor Cell Lymphoblastic Leukemia-Lymphoma
1
Noonan Syndrome 6
1
Interventions
Pemetrexed
9
Nivolumab
8
Cisplatin
8
Carboplatin
8
pembrolizumab
7
130-nm albumin-bound paclitaxel
7
Gemcitabine
6
padeliporfin
5
durvalumab
5
Paclitaxel
5
Bevacizumab
5
palbociclib
4
napabucasin
4
atezolizumab
4
Irinotecan
4
Fulvestrant
4
Fluorouracil
4
Drug Therapy
4
Cyclophosphamide
4
ribociclib
3
osimertinib
3
cobimetinib
3
alectinib
3
abemaciclib
3
Trastuzumab
3
Sunitinib
3
Radiosurgery
3
Mitomycin
3
Docetaxel
3
Cetuximab
3
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
2 trials
Recent
Start date
Enrollment
Neoplasms by Site
×
entrectinib
×
Clear all
NCT05722886
2025-11-24
DETERMINE
Cancer Research UK
Phase 2/3
Recruiting
825 enrolled
NCT05770544
2025-11-24
DETERMINE
Cancer Research UK
Phase 2/3
Recruiting
30 enrolled